25周年を記念 1999-2024
*3年間で¥ 153396、たったの¥ 61358
フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:April 28,
As filed with the Securities and Exchange Commission on April 15, 2020 Registration No. 333 ...
EDISON EQUITY RESEARCH: ANGLE: ADR UPDATE - THIRD CLINICAL APPLICATION EMERGESAngle has announced results from a metastatic breast cancer...
EDISON EQUITY RESEARCH: ANGLE - CELLS FOR PRECISION MEDICINEAngle has transformed into a pure-play diagnostics business. Parsortix, its...
ANGLE plc's Parsortix System Harvests CTCS In 100% Of Prostate Cancer Patients Barts study demonstrates Parsortix harvested cells are clinically...
ANGLE plc appoints Jim Reuben Scientific Adviser PR Newswire GUILDFORD, England, June 3, 2015 GUILDFORD, England, June 3, 2015 /PRNewswire/...
ANGLE plc Updates Results on Ovarian Cancer Study PR Newswire GUILDFORD, United Kingdom, April 21, 2015 GUILDFORD, United Kingdom, April 21, 2015...
Results From The Sidney Kimmel Cancer Center At Thomas Jefferson University PR Newswire GUILDFORD, England, April 20, 2015 GUILDFORD, England...
S&P Capital IQ Initiates Coverage on ANGLE Plc in S&P Capital IQ Factual Stock Reports PR Newswire NEW YORK, March 16, 2015 NEW YORK...
ANGLE plc ("Angle" or "the Company") Collaboration With MD Anderson Cancer Center On Colorectal Cancer PR Newswire GUILDFORD...
ANGLE plc ("the Company") Patient Data Shows "Unprecedented Sensitivity And Specificity" For Parsortix Ovarian Cancer...
ANGLE plc ("ANGLE" Or "The Company") Corporate Collaboration With Large Pharmaceutical Company PR Newswire GUILDFORD, United...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約